Aria CC:
No new news on partnership renegotiations, although the claim is they are progressing well. A few nuggets - Harvey says he has absolutely no intention of raising money, which to my mind must imply a 534 partnership in the next couple of months. Second, he said of patients that have responded initially to 534, none have progressed. Still early, but that hints at greater durability than existing agents. Still talking up their ALK inhibitor (2 abstracts at AACR) although no mention of when it will actually hit the clinic.
Peter
